Boston Scientific and Angiotech Pharmaceuticals receive Canadian American Business Council 2005 Achievement Award
08 November 2005 - 8:45PM
PR Newswire (US)
VANCOUVER, BC, and NATICK, MA, Nov. 8 /PRNewswire-FirstCall/ --
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) and its
corporate partner, Boston Scientific Corporation (NYSE:BSX)
announced today that they have jointly received the Canadian
American Business Council (CABC) 2005 Achievement Award, which
recognizes innovative and successful alliances between Canadian and
American firms. The award was presented today at the Council's 11th
annual business achievement awards ceremony and policy forum held
in Calgary, Alberta, Canada. The CABC Achievement Award is given
each year to two companies whose cross-border joint enterprise has
demonstrated strong business growth, remarkable innovation, and the
capacity to provide the allies with a global advantage. The winners
are chosen by an international panel of judges using standards that
examine sustained profitability, job creation, financial strength,
environmental responsibility, corporate synergy, exceptional
imagination and remarkable innovation. "We are very pleased that
our alliance with Angiotech has been recognized by the CABC," said
Jim Tobin, President and Chief Executive Officer of Boston
Scientific. "The innovative combination of our TAXUS(R) stent
technology with Angiotech's paclitaxel drug technology has resulted
in the world's most successful drug-eluting coronary stent system.
The 1.8 million stents implanted to date in patients worldwide is a
testament to the strength of the alliance, and to the employees at
Boston Scientific and Angiotech who made this revolutionary
technology possible." "This award is a tribute to the hard work and
dedication of employees at both companies," said William Hunter,
Chief Executive Officer of Angiotech. "The complexity of the joint
project was enormous but we were able to marry our separate
pharmaceutical and device technologies to deliver an innovative
combination product for the global market." Executives from Boston
Scientific and Angiotech also participated in a policy forum and
panel discussion titled "The Cross Border Security and Prosperity
Partnership". BSC acquired worldwide exclusive rights from
Angiotech to use paclitaxel to coat its coronary stent products and
has co-exclusive rights to other vascular and non-vascular
products. About The Canadian American Business Council The Canadian
American Business Council is the premier voice of the
Canadian-American business community and is headquartered in
Washington, D.C. Established in 1987, the Council is a non-profit,
issues-oriented organization dedicated to elevating the private
sector perspective on issues that affect Canada and the United
States. For more information, please visit
http://www.canambusco.org/. About Angiotech Pharmaceuticals
Vancouver-based Angiotech Pharmaceuticals, Inc., a specialty
pharmaceutical company focusing on drug-coated medical devices and
biomaterials, is dedicated to enhancing the performance of medical
devices and biomaterials through the innovative uses of
pharma-therapeutics. To find out more about Angiotech
Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), please visit our
website at http://www.angiotech.com/. About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad
range of interventional medical specialties. For more information,
please visit: http://www.bostonscientific.com/. Statements
contained herein that are not based on historical or current fact,
including without limitation statements containing the words
"anticipates," "believes," "may," "continue," "estimate,"
"expects," and "will" and words of similar import, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following:
general economic and business conditions, both nationally and in
the regions in which the Company operates; technology changes;
competition; changes in business strategy or development plans; the
ability to attract and retain qualified personnel; existing
governmental regulations and changes in, or the failure to comply
with, governmental regulations; liability and other claims asserted
against the Company; and other factors referenced in the Company's
filings with the United States Securities and Exchange Commission
or the Canadian securities regulators. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements. CONTACT:
Boston Scientific Angiotech Pharmaceuticals -----------------
------------------------- Milan Kofol Todd Young 508-650-8569
604-221-7676 ext 6933 Investor Relations VP Investor Relations
& Boston Scientific Communications Corporation Angiotech
Pharmaceuticals, Inc. Paul Donovan Rui Avelar 508-650-8541
604-221-7676 ext 6996 Media Relations Sr. VP Medical Affairs &
Boston Scientific Communications Corporation Angiotech
Pharmaceuticals, Inc. Colleen Beauregard 503-443-7863 Media
Relations Waggener Edstrom Bioscience DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Boston Scientific, Milan Kofol,
(508) 650-8569, Investor Relations, Boston Scientific Corporation;
Paul Donovan, (508) 650-8541, Media Relations, Boston Scientific
Corporation; Angiotech Pharmaceuticals, Todd Young, (604) 221-7676
ext 6933, VP Investor Relations & Communications, Angiotech
Pharmaceuticals, Inc.; Rui Avelar, (604) 221-7676 ext 6996, Sr. VP
Medical Affairs & Communications, Angiotech Pharmaceuticals,
Inc.; Colleen Beauregard, (503) 443-7863, Media Relations, Waggener
Edstrom Bioscience
Copyright